In addition to the chemotherapeutic drugs, such as bevacizumab and temozolomide, which inhibit VEGF in a paracrine loop and [10,91,92,93] provide the rationale to inhibit tumor progression, sorafenib, a multi-Tyrosine Kinase Inhibitor (mTKI), has been shown to restrict the action of VEGFR2, RAS kinase, and PDGFR, [94] targeting twofold PCs and ECs through the hindrance of the autocrine VEGF signaling loop [10]. The gene discussed is KDR; the disease is neoplasm.